Interius BioTherapeutics

Executive Summary

Interius BioTherapeutics is a preclinical-stage biotechnology company developing a proprietary LENTIVECTOR platform for in vivo delivery of genetic medicines. Founded in 2018 and headquartered in Philadelphia, the company aims to overcome the limitations of ex vivo cell therapies by engineering targeted lentiviral vectors that can program cells directly in the body, enabling off-the-shelf, single-dose treatments. Interius focuses on oncology and autoimmune diseases, with the goal of making advanced therapies faster, cheaper, and more accessible. While still in early development, the company's differentiated approach addresses key challenges in gene therapy, such as cell targeting, payload capacity, and manufacturing scalability. Interius is privately held and has not yet disclosed its financials or clinical-stage pipeline.

Upcoming Catalysts (preview)

• Q2 2027IND filing for lead program in oncology30% success
• Q4 2026Presentation of preclinical proof-of-concept data at major conference50% success
• Q2 2026Series A or B financing announcement60% success